三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
截至2025年2月,多款针对EGFRTKI耐药后NSCLC患者(全人群)的药物全球进度较快
截至2025年2月,多款针对EGFRTKI耐药后NSCLC患者(全人群)的药物全球进度较快
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:161KB
图片尺寸:2327*721
同报告图片
/
4
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
所属报告:
百利天恒-公司首次覆盖报告:双抗ADC领航者携手BMS开启国际化新纪元-250411(40页).pdf
打包全文图表
相关数据
ADC联合IO单抗治疗一线NSCLC全球三期研究启动时间
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
收藏
行业数据
2026-07-14
原图定位
查看详情
KRASG12C一线治疗NSCLC竞争格局(截至2026-6-25)
收藏
竞争格局
2026-07-01
原图定位
查看详情
全球KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
中国KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
SHR-A2009用于一线NSCLC患者的研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
PD(L)1*VEGF双抗单药针对一线NSCLC数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
各药物针对IO耐药NSCLC临床数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
驱动基因阴性晚期NSCLC治疗格局
收藏
竞争格局
2026-02-24
原图定位
查看详情
NSCLC1L全球竞争格局AK112BNT327707
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
收藏
竞争格局
2026-01-28
原图定位
查看详情
图23.2024年国内EGFRTKI市场份额
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
收藏
竞争格局
2026-01-13
原图定位
查看详情
SI-B001针对PD-(L1)抑制剂治疗失败的野生型NSCLC的mPFS数据
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
收藏
行业数据
2025-12-26
原图定位
查看详情
图表4国NSCLC驱动基因谱
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
收藏
行业数据
2025-12-03
原图定位
查看详情
图表11国内EGFRTKI样本医院销售额/及
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
收藏
行业数据
2025-12-03
原图定位
查看详情
图表20EGFR耐药后NSCLC试验数据比
PHxiZWdpbl9vZl9ib3h8Pnwg5rK755aX5py65Yi2ICAgICAgICAgfCDor5Xpqoznp7Dlj7cgICAgICAgfCDlrp7pqoznu4QgdnMg5a+554Wn57uEICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBPUlIg5pWw5o2uICAgICB8IG1QRlMv5pyIICAgICAgICAgICAgICAgICAgICAgfCBtT1Mv5pyIICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCDljZXmipcr5YyW55aXICAgICAgICB8IENoZWNrTWF0ZTcyMiAgIHwg57qz5q2m5Yip5bCk5Y2V5oqXK+WMlueWlyB2cyDljJbnlpcgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDMxJSB2cyAyNyUgICB8IDUuNiB2cyA1LjQgKEhSIDAuNzUpICAgICAgICAgfCAxOS40IHZzIDE1LjkgKEhSIDAuODIpICAgICAgIHwKfCDljZXmipcr5YyW55aXICAgICAgICB8IEtleW5vdGUtNzg5ICAgIHwgS+iNryvljJbnlpcgdnMg5YyW55aXICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyOSUgdnMgMjclICAgfCA1LjYgdnMgNS41IChIUiAwLjgpICAgICAgICAgIHwgMTUuOSB2cyAxNC43IChIUiAwLjg0KSAgICAgICB8Cnwg5Y2V5oqXK+i0neS8kOePoCvljJbnlpcgfCBPUklFTlQtMzEgICAgICB8IOS/oei/quWIqeWNleaKlyvotJ3kvJDnj6Ar5Z+5576O5puy6LWbK+mhuumTgiB2cyDln7nnvo7mm7LotZsr6aG66ZOCICAgICAgIHwgNDglIHZzIDI5JSAgIHwgNy4yIHZzIDQuMyAoSFIgMC41MSkgICAgICAgICB8IDIxLjEgdnMgMTkuMiAoSFIgMC45OCkgICAgICAgfAp8IOWNleaKlyvotJ3kvJDnj6Ar5YyW55aXIHwgT1JJRU5ULTMxICAgICAgfCDkv6Hov6rliKnljZXmipcr5Z+5576O5puy6LWbK+mhuumTgiB2cyDln7nnvo7mm7LotZsr6aG66ZOCICAgICAgICAgICAgICB8IDM1JSB2cyAyOSUgICB8IDUuNSB2cyA0LjMgKEhSIDAuNzIpICAgICAgICAgfCAyMC41IHZzIDE5LjIgKEhSIDAuOTcpICAgICAgIHwKfCDljZXmipcr6LSd5LyQ54+gK+WMlueWlyB8IEFUVExBUyAgICAgICAgIHwg6Zi/5pu/5Yip54+g5Y2V5oqXK+i0neS8kOePoCvljaHpk4Ir57Sr5p2J6YaH77yIQUJDUOaWueahiO+8iSB2cyDljaHpk4Ir57Sr5p2J6YaH77yIQ1DmlrnmoYjvvIkgfCA3MCUgdnMgNDIlICAgfCA4LjQ4IHZzIDUuNjIgKEhSIDAuNjIpICAgICAgIHwgMjAuNiB2cyAyMC4zIChIUiAxLjAxKSAgICAgICB8Cnwg5Y+M5oqXK+WMlueWlyAgICAgICAgfCBIQVJNT05pLUEgICAgICB8IEFLMTEyK+Wfuee+juabsui1myvljaHpk4IgdnMg5Z+5576O5puy6LWbK+WNoemTgiAgICAgICAgICAgICAgICAgICB8IDUxJSB2cyAzNSUgICB8IDcuMSB2cyA0LjggKEhSIDAuNDYpICAgICAgICAgfCAxNi44IHZzIDE0LjEgKEhSIDAuNzQpICAgICAgIHwKfCBUUk9QMiBBREMgICAgICAgIHwgT3B0aVRST1AtTHVuZzA0fCDoiqblurfmspnlpqXnj6DljZXmipfljZXoja8gdnMg5Z+5576O5puy6LWbK+mTguexuyAgICAgICAgICAgICAgICAgICAgIHwgNjAuNiUgdnMgNDMuMSUgfCBCeSBCSUNSIDguMyB2cyA0LjMgKEhSIDAuNDkpIHwgTlIgdnMgMTcuNCAoSFIgMC42KSAgICAgICAgICB8CnwgRUdGUi9jLU1ldOWPjOaKlyAgIHwgTUFSSVBVU0EtMiAgICAgfCDln4PkuIflpqUr5ouJ5rO95pu/5bC8K+WMlueWlyB2cyDljJbnlpcgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDYzJSB2cyAzNiUgICB8IDguMyB2cyA0LjIgKEhSIDAuNDQpICAgICAgICAgfCDmnKrmiJDnhp8gICAgICAgICAgICAgICAgICAgICAgIHwKfCBFR0ZSL2MtTWV05Y+M5oqXICAgfCBNQVJJUFVTQS0yICAgICB8IOWfg+S4h+WmpSvljJbnlpcgdnMg5YyW55aXICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA2NCUgdnMgMzYlICAgfCA2LjMgdnMgNC4yIChIUiAwLjQ4KSAgICAgICAgIHwg5pyq5oiQ54afICAgICAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupA6IOOAilRoZSBjaGFuZ2luZyB0cmVhdG1lbnQgbGFuZHNjYXBlIG9mIEVHRlIgLSBtdXRhbnQgbm9uIC0gc21hbGwgLSBjZWxsIGx1bmcgY2FuY2Vy44CLLCBGZWkgWmhvdSwgSGF1eXVlIEd1byDnrYnkuro7IDIwMjXlubQgU0lUQyDlpKfkvJo8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-12-03
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
HER3 的高表达在很多癌症中也与疾病进展或预后不佳有关,公司 BL-B01D1(EGFRxHER3 ADC)进度全球居前。EGFR⁃TKI耐药分为原发性耐药和获得性耐药,两者耐药机制包括:EGFR 依赖性耐药、由 EGFR 旁路或下游信号通路激活导致的非 EGFR依赖性耐药,以及组织学或表型转化,还有一部分患者耐药机制未知。针对不同耐药机制,目前已开发出多种治疗策略。其中,HER3的高表达在很多癌症中也与疾病进展或预后不佳有关,会导致患者对多种治疗药物产生耐药性。截至 2025年 2月,已有多款针对 EGFR TKI耐药后 NSCLC患者(全人群)的药物处于临床后期。其中,康方生物的依沃西单抗已于 2024年 5月 21日在中国获批上市,用于治疗 EGFR TKI耐药后进展的 NSCLC患者。公司 BL-B01D1针对此适应症已于 2024年 4月 24日进入 III期注册临床。
行业数据
原图定位
当前图表所属:
百利天恒-公司首次覆盖报告:双抗ADC领航者携手BMS开启国际化新纪元-250411(40页).pdf
晚期三阴性乳腺癌患者以化疗为主要治疗手段
BL-B01D1早期临床展现优秀的mPFS数据
晚期ES-SCLC患者的二线治疗方案以单药化疗为主
针对2L+EGFRwt患者,BL-B01D1早期临床数据展现良好治疗潜力
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》